Press Releases
-
AES Clean Technology enhances cleanroom construction capabilities through new senior appointment
-
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing
About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics completed Bio Campus I with Plant 4, offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 180KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Samsung Biologics Media Contact Claire Kim, Head of Marketing Communications cair.kim@samsung.com About LegoChem Biosciences, Inc. LegoChem Biosciences (KOSDAQ: 141080) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on researching and developing Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics, and anti-fibrotic based on proprietary platform technologies. For more information, visit LegoChem Biosciences, Inc. at https://www.legochembio.com/index.php?lang=e LegoChem Biosciences Media Contact Daeyoung Jeong, Team Leader of IR/BD jdy@legochembio.com
Feb 6, 2024
-
Alfa Chemistry Releases Carbomer Series Products for Cosmetics and Personal Care Products Manufacturing
-
CD Formulation Shows the Ability of Coated Microneedle Preparation Technology for Novel Drug Delivery
-
Alfa Chemistry Catalysts: Porphyrin Ligands, Phthalocyanine Ligands Are Newly Released for the Science Community
-
Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints
Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints RBQM Leader Shortlisted for Accolade for Innovation in the Management of Clinical Data
Feb 5, 2024
-
Azenta Launches the BioArc Ultra, a Breakthrough, Automated Solution for Efficient, Eco-Friendly Ultracold Sample Management
Azenta, Inc has announced the launch of the BioArc™ Ultra, a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance.
Feb 4, 2024
-
Quantify Research Opens New Office in Finland
Quantify Research has announced the opening of its new office today in Helsinki, Finland.
Feb 4, 2024
-
Showcase on lab automation instruments and consumables on display at SLAS2024 International Conference and Exhibition
Azenta Life Sciences has announced that it will display a range of productivity-enhancing consumables, instruments, and automated sample storage products at SLAS 2024 in Boston, USA from February 5 - 7.
Feb 4, 2024
-
Verisense Health Adopts Datavant’s Data Connectivity Platform to Expand its Digital Health Panel’s RWD Sources
Datavant’s privacy-preserving record linkage technology will allow Verisense Health’s digital health data to generate richer patient insights.
Feb 5, 2024
-
Bourne Partners Advises Clincierge on its Sale to Greenphire
Greenphire, a leading innovator in software solutions for streamlining clinical trials, proudly announces the acquisition of Clincierge, a premier provider of concierge travel and logistics support for patients participating in clinical trials. This strategic move is poised to revolutionize the landscape of clinical trial support services by integrating unparalleled patient care with cutting-edge technology.
Jan 31, 2024
-
Lindus Health Introduces Bespoke “All-In-One CRO for Digital Therapeutics” Solution to Companies in the Space Streamline Clinical Trials
Lindus Health Introduces Bespoke “All-In-One CRO for Digital Therapeutics” Solution to Companies in the Space Streamline Clinical Trials
Jan 31, 2024
-
Effortless Measurement of All Four NADs and Glutathione for Laboratories
NADMED has announced an innovative technology designed for effortless extracting and measuring all four NADs and two glutathiones.
Jan 31, 2024
-
Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults
-
Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology
Infinity Bio, Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This platform offers unparalleled depth in immune system analysis, advancing immunology, virology, autoimmunity, and allergy research, providing new disease insights, and discovering new biomarkers and treatments. The MIPSA technology exploits recent advances in high throughput DNA sequencing and DNA synthesis, to create and analyze the most complete panels of immune targets available.
Jan 30, 2024
-
Creative Enzymes Revolutionizes the Field with Advanced Industrial Enzyme Production Service
-
Creative Enzymes Introduces Pyranose Oxidase from Microorganism for Enhanced Industrial Applicability
-
Creative Proteomics Bolsters Its Position in Biomarker Discovery with N-Glycan and O-Glycan Profiling Services
-
Creative Proteomics Offers Advanced Steroids Analysis Service for Medical Industry
-
Cresset Aims to Optimise Drug Discovery with Latest Drug Design Platform Release
Drug discovery specialists Cresset have just released a new version of their drug discovery platform Flare
Jan 28, 2024